D L Kleinberg

Summary

Affiliation: New York University
Country: USA

Publications

  1. ncbi Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions
    David L Kleinberg
    Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, New York 10016, USA
    Endocr Rev 30:51-74. 2009
  2. ncbi Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice
    David L Kleinberg
    The Bunnie Joan Sachs Laboratory, Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Endocrinology 148:1080-8. 2007
  3. ncbi New roles and challenges in neurosurgery of acromegaly
    D L Kleinberg
    Neuroendocrine Unit, New York University School of Medicine, New York, USA
    J Endocrinol Invest 28:88-91. 2005
  4. ncbi IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis
    D L Kleinberg
    Department of Medicine, New York University School of Medicine and Department of Veterans Affairs Medical Center, New York 10010, USA
    J Mammary Gland Biol Neoplasia 5:7-17. 2000
  5. ncbi Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development
    W Ruan
    Department of Medicine, New York University School of Medicine, and Department of Veterans Affairs Medical Center, New York 10010, USA
    Endocrinology 140:5075-81. 1999
  6. ncbi Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development
    W Ruan
    Department of Medicine, New York University School of Medicine, and the Department of Veterans Affairs Medical Center, New York 10016, USA
    Endocrinology 140:1984-9. 1999
  7. ncbi Lipid metabolism in phosphatidylinositol transfer protein alpha-deficient vibrator mice
    Marie E Monaco
    Department of Urology, NYU School of Medicine, New York, NY 10016, USA
    Biochem Biophys Res Commun 317:444-50. 2004
  8. ncbi IGF-I, GH, and sex steroid effects in normal mammary gland development
    David L Kleinberg
    Bunnie Joan Sachs Laboratory, VA Medical Center, New York, NY, USA
    J Mammary Gland Biol Neoplasia 13:353-60. 2008
  9. ncbi SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
    Weifeng Ruan
    Neuroendocrine Unit, New York University School of Medicine, New York, New York 10016, USA
    Mol Endocrinol 20:426-36. 2006
  10. ncbi Diagnosis and management of growth hormone deficiency in adults
    S Stavrou
    Department of Medicine, New York University School of Medicine, New York, New York, USA
    Endocrinol Metab Clin North Am 30:545-63. 2001

Research Grants

  1. MAMMARY CARCINOGENESIS--GROWTH HORMONE AND IGF-I
    David Kleinberg; Fiscal Year: 2001
  2. Mammary Carcinogenesis: Growth Hormone and IGF-I
    David Kleinberg; Fiscal Year: 2006

Collaborators

Detail Information

Publications17

  1. ncbi Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions
    David L Kleinberg
    Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, New York 10016, USA
    Endocr Rev 30:51-74. 2009
    ....
  2. ncbi Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice
    David L Kleinberg
    The Bunnie Joan Sachs Laboratory, Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Endocrinology 148:1080-8. 2007
    ..The work also provides a rationale for considering IGF-I inhibition as therapy for BPH to reduce the size of both prostate compartments...
  3. ncbi New roles and challenges in neurosurgery of acromegaly
    D L Kleinberg
    Neuroendocrine Unit, New York University School of Medicine, New York, USA
    J Endocrinol Invest 28:88-91. 2005
    ..It has been estimated that life expectancy is shortened by about 10 yr overall, and longer when diabetes or heart disease are already present at the time of diagnosis...
  4. ncbi IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis
    D L Kleinberg
    Department of Medicine, New York University School of Medicine and Department of Veterans Affairs Medical Center, New York 10010, USA
    J Mammary Gland Biol Neoplasia 5:7-17. 2000
    ..GH-induced IGF-I is of major importance in ductal morphogenesis, and may, in fact, be necessary for later stages of mammary development, as well...
  5. ncbi Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development
    W Ruan
    Department of Medicine, New York University School of Medicine, and Department of Veterans Affairs Medical Center, New York 10010, USA
    Endocrinology 140:5075-81. 1999
    ..These results suggest that IGF-I, when given along with E2, is responsible for ductal morphogenesis...
  6. ncbi Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development
    W Ruan
    Department of Medicine, New York University School of Medicine, and the Department of Veterans Affairs Medical Center, New York 10016, USA
    Endocrinology 140:1984-9. 1999
    ....
  7. ncbi Lipid metabolism in phosphatidylinositol transfer protein alpha-deficient vibrator mice
    Marie E Monaco
    Department of Urology, NYU School of Medicine, New York, NY 10016, USA
    Biochem Biophys Res Commun 317:444-50. 2004
    ..No differences are observed in any aspect of lipid-mediated signal transduction...
  8. ncbi IGF-I, GH, and sex steroid effects in normal mammary gland development
    David L Kleinberg
    Bunnie Joan Sachs Laboratory, VA Medical Center, New York, NY, USA
    J Mammary Gland Biol Neoplasia 13:353-60. 2008
    ....
  9. ncbi SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
    Weifeng Ruan
    Neuroendocrine Unit, New York University School of Medicine, New York, New York 10016, USA
    Mol Endocrinol 20:426-36. 2006
    ....
  10. ncbi Diagnosis and management of growth hormone deficiency in adults
    S Stavrou
    Department of Medicine, New York University School of Medicine, New York, New York, USA
    Endocrinol Metab Clin North Am 30:545-63. 2001
    ..Longer prospective clinical studies are needed. The major manufacturers of growth hormone have initiated postmarketing surveillance databases to monitor the safety of growth hormone treatment...
  11. ncbi Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action
    Weifeng Ruan
    Neuroendocrine Unit, Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, New York 10016, USA
    Endocrinology 146:1170-8. 2005
    ....
  12. ncbi Role of IGF-I in normal mammary development
    D L Kleinberg
    Veterans Administration and New York University Medical Centers, New York, NY 10010, USA
    Breast Cancer Res Treat 47:201-8. 1998
    ..One of the mechanisms for this effect involves apoptosis. The potential role of GH or IGF-I in mammary carcinogenesis, and the applicability of animal studies to humans, are discussed...
  13. ncbi Rheumatic manifestations of pituitary tumors
    S Stavrou
    NYU School of Medicine, 423 East 23rd Street, New York, NY 10010, USA
    Curr Rheumatol Rep 3:459-63. 2001
    ..Pituitary tumors can have manifestations similar to rheumatologic disorders and should be included in the differential diagnosis of these diseases...
  14. ncbi GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90
    John D Carmichael
    Neuroendocrine Unit, Division of Endocrinology, General Clinical Research Center, New York University School of Medicine, New York, NY, USA
    Clin Endocrinol (Oxf) 65:169-77. 2006
    ....
  15. ncbi Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development
    Daniela Milani
    Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    J Clin Endocrinol Metab 89:2271-4. 2004
    ..The results also suggest that variability in IGF-I should be taken into account when designing such studies...
  16. ncbi Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs
    David L Kleinberg
    Neuroendocrine Unit, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Rev Endocr Metab Disord 6:29-37. 2005
  17. ncbi Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency
    Beverly M K Biller
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 87:2067-79. 2002
    ..The ARG plus GHRH test represents an excellent alternative to the ITT for the diagnosis of GH deficiency in adults...

Research Grants11

  1. MAMMARY CARCINOGENESIS--GROWTH HORMONE AND IGF-I
    David Kleinberg; Fiscal Year: 2001
    ..We suggest that understanding control of normal mammary development will eventually result in novel insights into mammary carcinogenesis. ..
  2. Mammary Carcinogenesis: Growth Hormone and IGF-I
    David Kleinberg; Fiscal Year: 2006
    ..The potential role of IGF-I as a permissive factor for the action of PRL will also be determined. ..